Pharmaceutical comprising (2R)-2-[[(4-chlorophenyl)sulfonyl][[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoropentanamide with enhanced bioavailability and solubility
Disclosed is an alpha-(N-sufonamido)acetamide derivative as part of a pharmaceutical composition comprising: (2R)-2-[[(4-chlorophenyl)sulfonyl][[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoropentanamide, Polyethylene glycol (PEG), Vitamin E polyethylene glycol succinate (TPGS), A crystallization inhibitor member selected from the group consisting of polyvinylpryrrolidone (PVP) and copovidone (PVP-Polyvinyl acetate), and Citric acid. The pharmaceutical composition is a Beta amyloid peptide production inhibitor and is useful for treating Alzheimers disease, cerebral amyloid angiopathy, mild cognitive impairment and/or Down syndrome, as well as the treatment of head trauma, traumatic brain injury, and/or dementia pugilistica.
